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Abstract
Ochratoxin-A (OTA) is a mycotoxin with possibly carcinogenic and nephrotoxic effects in humans and animals. OTA is often
found as a contaminant in agricultural commodities. The aim of the present work was to evaluate OTA-degrading and
detoxifying potential of Cupriavidus basilensis O˝R16 strain. In vivo administration of OTA in CD1 male mice (1 or 10 mg/kg
body weight for 72 hours or 0.5 mg/kg body weight for 21 days) resulted in significant elevation of OTA levels in the blood,
histopathological alterations- and transcriptional changes in OTA-dependent genes (annexinA2, clusterin, sulphotransferase
and gadd45 and gadd153) in the renal cortex. These OTA-induced changes were not seen in animals that have been treated
with culture supernatants in which OTA was incubated with Cupriavidus basilensis O˝R16 strain for 5 days. HPLC and ELISA
methods identified ochratoxin a as the major metabolite of OTA in Cupriavidus basilensis O˝R16 cultures, which is not toxic in
vivo. This study has demonstrated that Cupriavidus basilensis O˝R16 efficiently degrade OTA without producing toxic
adventitious metabolites.
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Introduction
Ochratoxin-A (OTA) is a hazardous mycotoxin produced by
number of Aspergillus and Penicillium species [1]. Mycotoxins are
extracellular secreted secondary metabolites of moulds that are
harmful or toxic to animals and humans [2]. The chemical
structure of OTA molecule (N-{[(3R)-5-chloro-8-hydroxy-3-meth-
yl-1-oxo-3,4-dihydro-1H-isochromen-7-yl]carbonyl}-L-phenylala-
nine) includes a b-phenylalanine-dihydroisocoumarine derivative,
which is very stable at high temperature and resistant to
hydrolysis, hence processing of raw materials in feed and food
industry does not eliminate the OTA and the toxin remains intact
in the end-products. The OTA is often found as a contaminant in
cereal grains or other crops and plant products such as red wine,
coffee beans, peanuts, cocoa beans, and different spices [3-5].
Dried Distillers Grains with Solubles (DDGS) remaining after
bioethanol production from maize is a valuable protein source for
animal nutrition, but high mycotoxin content of DDGS limits its
application [6]. On the other hand, the mycotoxin is also capable
to accumulate in several animal-derived food products (meat, egg,
blood and milk products) [7].
Chronic OTA exposure is the major causative chemical of
mycotoxin-induced porcine nephropathy [8,9] and Balkan
endemic nephropathy (BEN) in humans [10-13]. The OTA-
induced nephropathy is characterized by degeneration of epithelial
cells in the renal proximal tubules, glomerulus degeneration in
renal cortex area and interstitial fibrosis resulting in polyuria and
various changes in hematological and biochemical parameters
[14]. On the other hand, chemical structure of OTA shows
similarity to the amino acid phenylalanine, thus the toxin is able to
interrupt the protein synthesis [15,16]. Influence of OTA as a
causal chemical substance of different types of cancer such as renal
adenocarcinoma and liver tumor have been described in
laboratory rodents and in humans, as well [17,18]. OTA affects
the expression of several genes related to cell damage, apoptosis,
cellular stress, such as Growth arrest and DNA-damage-inducible
proteins (gadd45 and gadd153), annexins, sulfotransferase and
clusterin [19].
Several strategies can be used to reduce OTA levels in animal
feed and human food. The most important are preventive
methods since they avoid the contamination of commodities in
the first place. However, fully implemented Hazard Analysis and
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Critical Control Points (HACCP) schemes are rare, and when the
individual measures fail or are not in place, OTA remains in feed
and food products. Decontamination or detoxification procedures
can be used to remove or to reduce OTA levels. Remediation
processes are often used to eliminate, reduce or avoid the toxic
effects of OTA. The widely used physical adsorbents have some
disadvantages including limited efficiency, high cost and nonspe-
cific binding of some important nutrients, such as vitamins or
minerals and therapeutic agents. Biological methods have been
considered as an alternative to physical and chemical treatments.
The biodegradation is the most promising approach to control
mycotoxins and these methods are important postharvest strate-
gies to protect the animal and consumer health.
Several enzymes may be involved in the microbiological
degradation of OTA. However, little information is available
and very few have been purified and characterized. The first
reported protease able to hydrolyze OTA was carboxypeptidase A
(CPA) (EC 3.4.17.1) from bovine pancreas [20].
Previously more than fifteen species of bacteria [21] have been
shown to degrade OTA – but not yet any Cupriavidus species –
and many species of fungi have also been reported. However, vast
majority of this biodegradation by microorganisms cannot be
regarded as detoxification since the toxicity after the biotransfor-
mation was not elucidated. To develop a bacterial strain to
efficient biodegradation of OTA, selection of the most active and
environmentally safe microbes is required. The aim of the present
work was to evaluate the OTA-degrading and detoxifying
potential of a Cupriavidus basilensis strain, which mycotoxin-
degrading ability was presumable based on its genome project
[22].
Traditional chemical analysis and immunochemical methods
are unable to detect the toxic effect of all potential degradation
products; therefore it is important to monitor toxicity in vivo.
Moreover, the European Food Safety Authority reported that
contamination of animal feed by mycotoxins may be reduced by
mycotoxin-detoxifying agents but the additive effects of the
resulting metabolite(s)/degradation products(s) must also be
monitored in appropriate toxicological studies. Thus, development
of in vivo studies is essential to investigate biodegradation and
detoxification efficiency directly on the renal cortical area, the
most sensitive organ for OTA in animals and humans, as well. For
this purpose the application of a rodent based in vivo toxicological
experiment can be the most suitable approach, in which two
markers are analysed: alterations in the kidney and spleen weight
and changes in the expression of OTA-affected genes in the kidney
tissue [19]. This method in combination with analytical and
immunochemical techniques was applied to analyse OTA and
residuals toxicity after biodegradation.
Materials and Methods
2.1 Reagents
Ochratoxin-A (OTA) (Fermentek, Israel), methyl- methanesul-
fonate (MMS) (Sigma-Aldrich Co., USA), OTalpha standard
(Biopure, cat. number: BRM S02053, lot. number: L12503A),
dimethyl-sulfoxid - DMSO (Sigma-Aldrich Co., USA), Tris-
(hydroximethyl)- aminomethane, Tris (Sigma_Aldrich, USA),
modified Luria-Bertani (LB) medium (1 g triptone, 0,5 g yeast
extract, 0,9 g NaCl in 1000 ml distilled water) were used.
2.2 Bacterial strain and culture conditions in the
biodegradation test
The strain Cupriavidus basilensis O˝R16, was isolated from a
Hungarian pristine soil sample. It was identified by molecular
taxonomy as C. basilensis and deposited in the National Collection
of Agricultural and Industrial Microorganisms (NCAIM BO2487).
Cells were streaked on LB agar plates and incubated at 28uC for
72 h. Single colonies were inoculated into 50 ml liquid LB
medium and incubated at 170 rpm at 28uC for 72 h. The optical
density of the cultures was adjusted to 0.6 (OD600 = 0.6) and 50 ml
was added to 1350 ml sterile modified LB medium to which OTA
(28 mg OTA was dissolved in the 1400 ml modified LB medium)
had been added reaching a 20 mg/l final concentration. A no
inoculated control with 20 mg/l OTA content and a control
culture without OTA was applied. Control culture was essential
since in toxicity testing animals are presumably sensitive to
metabolic by-products of the C. basilensis O˝R16 strain. Samples
were incubated (170 rpm, 28uC) for 5 days. One-millilitre samples
from the flasks were removed at the 1st, 2nd, 3rd, 5th day,
centrifuged at 25,0006g at 4uC for 20 min and both supernatant
and pellet were stored at 220uC until further use. At the 5th day
(end-point) of the experiment the entire pellet material was
removed (25,0006g at 4uC for 20 min) and the supernatant was
concentrated by a factor of 100 on an Edwards Micromodulyo
lyophilisator and the lyophilised supernatant was used in the
animal experiments. Remaining OTA concentrations in the
supernatant were analyzed by High Performance Liquid Chro-
matography (Wessling Hungary Ltd., Hungary) and the superna-
tant and pellet were analysed by ELISA (Soft Flow Ltd., Hungary).
2.3 Analysis of samples for remaining toxin concentration
2.3.1 Enzyme-linked immunosorbent assay
(ELISA). The OTA toxin concentrations at the zero point in
the supernatant and also in the pellet on the 1st, 2nd, 3rd and 5th
day of the degradation experiment were determined by TOXI-
WATCH ELISA kit (Cat#301051, Soft Flow Hungary R& D
Ltd., Hungary) according to the manufacturer’s specifications.
Assay range: (0.1375 ng/ml–44 ng/ml, limit of detection:
0.130 ng/ml). 0.1M PBS buffer with 3% sodium-hydrogen-
carbonate NaHCO3, (4:1 v/v%) was used for sample dilution,
while standards contain the same solution (PBS/3% NaHCO3 4:1
ratio).
The 201052-5G9 (Soft Flow Hungary Ltd., Hungary) mono-
clonal antibody specifically binds to the mycotoxin OTA. The
immunogen used to generate the hybridoma 5G9 was OTA-BSA
conjugate. The 201052-5G9 antibody cross-reacts with ochratox-
in-B (9.3%). Measurements were carried out in triplicate and the
measurements were performed on Thermo Scientific Multiskan
EX photometric microplate absorbance reader.
2.3.2 High-performance liquid chromatography
(HPLC). HPLC analyses were carried out by Wessling Hungary
Ltd., an accredited laboratory, using a HPLC series 1100 from
Agilent Technologies, USA.
The supernatant collected at the beginning and on the 1st, 2nd,
3rd, 5th day of the degradation experiment, was analyzed for OTA
and its derivative OT-a. The bacterial pellet was suspended in
1 ml methanol and centrifuged (3,0006g for 10 min at ,10uC),
then the supernatant was analysed for OTA. Results for
degradation potential were corrected with the pellet analysis.
Protocols for the immuno-affinity column cleaning, derivatiza-
tion, LC separation and fluorescence detection of the compounds
were carried out according to European Standard (EN) and
International Organization for Standardization (ISO) (EN ISO
15141-1:2000 standard) for OTA. For the determination of OTa,
the column, eluent composition and detection parameters were
modified (see in Supplementary Materials, Table S1). HPLC
measurements were carried out in triplicates.
New Ochratoxin A Biodegradation Strategy Using Cupriavidus basilensis
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e109817
2.4 Animals
Adult, 7–9 week old, male CD1 mice (from the colony breed at
the Institute of Experimental Medicine, Budapest) were used.
Animals had free access to rodent food and water and were
maintained under controlled conditions (temperature, 2161uC;
humidity, 65%; light-dark cycle, 12-h light/12-h dark, lights on at
07:00). All procedures were conducted in accordance with the
guidelines set by the European Communities Council Directive
(86/609 EEC) and the protocol was approved by the Institutional
Animal Care and Use Committee of the Institute of Experimental
Medicine, Budapest Hungary (permit number: PEI/001/35-4/
2013).
2.5 Measuring of the blood OTA concentrations by ELISA
Extraction of OTA was carried out from 50 ml plasma sample
with 100 ml chloroform (Sigma-Aldrich Co., USA) and 10ml 0.1 M
H3PO4. The mixture was vortexed and incubated on Bio RS-24
vertical rotator (Biosan) rotating 25 rpm for 20 min then vortexed
again and centrifuged for 10 min at 100006 g. The lower phase
was transferred to a microcentrifuge tube, vortexed with 100 ml
3% (w/v) NaHCO3 solution, and incubated on the vertical rotator
(25 rpm, 10 min). The phases were let to split and the upper phase
was used for further measurements.
The OTA concentration of the extract was measured by Toxi-
Watch OTA ELISA Kit (Cat#301051, Soft Flow Hungary Ltd.,
Hungary). Measurements were performed on a Thermo Scientific
Multiskan EX photometric microplate absorbance reader. Mea-
surements were carried out in triplicate. The recovery was 77.6
65.42 % as was measured with 20 ng/ml OTA spiked blood
plasma samples.
2.6 Animal treatment
Male CD1 mice were housed and treated according to OECD
guideline for the testing of chemicals No. 407 with full access to
food and drinking water. Body weight, food and water consump-
tion was recorded daily. OTA was dissolved in DMSO and a stock
solution in 100 mg/ml OTA concentration was prepared, stored
at 4uC. Thereafter this master solution was diluted into sterile
drinking water containing 10 mM Tris (pH 8) to reach the
required experimental OTA dose. OTA and vehicle solutions
were administered daily via oral gavage (200ml/animal) in the
morning hours.
For testing OTA, three different dosage groups (n = 7-10/
group) were formed. For acute tests 1 mg/kg bw and 10 mg/kg
bw sacrificed after 72 h; for chronic test 0.5 mg/kg bw, sacrificed
after 21 day. Sterile drinking water supplemented with 10 mM
Tris and equal concentration of DMSO with high dose OTA
group in acute experiment and equal concentration of DMSO
with chronic experiment were applied as control. As genotoxic
control, MMS was used in 100 mg/kg bw dose for the 72 h
experiment and 40 mg/kg bw dose for the 21 day experiment
[23].
For testing OTA detoxification by C. basilensis O˝r16, samples
and controls originated from the degradation experiment were
applied (section 2.2). The lyophilized supernatant from the
biodegradation experiment with C. basilensis O˝r16 strain was
dissolved in 11.2 ml sterile tap water containing Tris and DMSO
following the same procedures that used in high OTA content
preparation (10 mg/kg bw). The theoretical OTA concentration
of this solution is 2.5 mg/ml, calculated by initial OTA quantity
(28 mg OTA). This stock solution was used for the treatment of
high OTA deg group (group treated with theoretical 10 mg/kg
body weight Ochratoxin A). Forty ml from this solution was added
to each 10g body weight (0.1 mg theoretical OTA quantity).
Following dilutions were made from this stock solution for the
lower OTA deg groups treatment (group treated with 1 mg/kg
body weight and 0.5 mg/kg bw Ochratoxin A) by using sterile tap
water containing 10 mM Tris (pH 8) and balanced DMSO. Doses
were calculated from the animal weights and administered via oral
gavages.
The animal treatment with intact Ochratoxin A and the
biodegradation experiment were carried out from same OTA
batch. Animals were decapitated, trunk blood collected on ice,
spleen and kidney were removed and their weights were measured.
Kidney was cut longitudinally resulting in half kidneys. One half
was fixed in 10% buffered formalin solution for histological
examination. From the other half of the kidney, the cortex and
medulla were separated and frozen immediately in dry ice and
stored at 280uC to prevent RNA degradation.
2.7 Quantitative Real-Time PCR
Frozen kidney cortex tissue samples were homogenized by IKA
Ultra Turrax in TRI Reagent Solution (Ambion, USA) and total
RNA was isolated with QIAGEN RNeasy Mini Kit (Qiagen,
USA) according the manufacturer’s instruction. To eliminate
genomic DNA contamination DNase I treatment were used and
100 ml Rnase-free DNase I (1 unit DNase) (Thermo Scientific,
USA) solution was added. Sample quality control and the
quantitative analysis were carried out by NanoDrop (Thermo
Scientific, USA). Amplification was not detected in the RT-minus
controls. The cDNA synthesis was performed with the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
USA). Primers for the comparative Ct experiments were designed
by Primer Express 3.0 Program. The primers (Microsynth,
Balgach) were used in the Real-Time PCR reaction with Fast
EvaGreen qPCR Master Mix (Biotium, USA) on ABI StepOne-
Plus instrument was listed in Table S2.
List of the genes: peptidylprolyl isomerase A (ppia,
NM_008907), annexin A2 (anxa2, NM_007585), clusterin (clu,
NM_013492), DNA-damage inducible transcript 3 (gadd153,
NM_007837), growth arrest and DNA-damage-inducible 45 alpha
(gadd45a, NM_007836) and sulfotransferase (sult1c2,
NM_026935).
The gene expression was analyzed by ABI Step One 2.1
program. The amplicon was tested by Melt Curve Analysis on ABI
Step OnePlus Instrument. Experiments were normalized to ppia
(peptidylprolyl isomerase A) expression [24].
2. 8 Histology
Formalin fixed kidney samples were processed and embedded in
paraffin using the standard protocol. Sections of 4 mm were
stained with haematoxylin and eosin. Slides were analysed by an
expert veterinary pathologist in a blinded manner.
2.9 Statistical analysis
Data are expressed as means 6 SD. The data were first
subjected to a Kolmogorov-Smirnov normality test. Data passing
this test, were analyzed by One way ANOVA followed by the
Tukey’s post hoc test. Data showed non-Gaussian distribution, the
Kruskal-Wallis test was used. Statistical analysis was performed
using GraphPad PRISM version 6 software (GraphPad Software,
USA). P # 0.05 was considered significant.
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Results
3.1 Ochratoxin-A biodegradation by Cupriavidus
basilensis O˝R16
The biodegradation ability of Cupriavidus basilensis O˝R16
strain to detoxify OTA was monitored by different analytical
approaches. The HPLC and ELISA results are summarised in
Fig. 1, where samples originating from the OTA degradation
experiments (1st, 2nd, 3rd, 5th day) are indicated as a function of
time. OTA concentration in the no inoculated control remained
20 mg/l during the incubation (5 days) measured by HPLC and
ELISA. In the bacterial pellet ELISA detected lower than 0.004%
residual OTA of the original concentration (20 mg/l). The first
day of incubation Cupriavidus basilensis O˝R16 cells degraded
0.15% of the initial OTA content, but this OTA content reduced
by the 5th day below 0.004%, thus OTA elimination from the
matrix was attributed to metabolic activity. OTA content in the
supernatants reduced continuously during the 5-day incubation
and the OTA was completely degraded (94% decrease measured
by ELISA, 100% decrease by HPLC). Based on the HPLC results
OTA was metabolized to OTa, since OTa content increased in
parallel by OTA decrease.
3.2 Water, food consumption and body weight change of
mice
Food and water consumption did not change significantly
during acute or chronic OTA administration with the supernatant
samples from biodegradation study. Body weight of the treated
animals in either experiment also did not alter significantly.
3.3 Blood OTA content in acute and chronic toxicities
Low levels of OTA were detected in the blood of vehicle or
MMS-treated control animals (5.306 3.9 and 3.2064.9 ng/ml
respectively). Acute mycotoxin treatment significantly elevated
OTA concentration in the blood OTA 1 (269.73 6 60.6 ng/ml
OTA in blood plasma, p = 0.0055), and OTA 10 (1969.28
6654.6 ng/ml OTA in blood plasma, p = 0.0023) groups.
However, significantly lower levels of OTA were detected in
plasma samples of mice treated with 10 mg/kg bw biodegraded
OTA products in acute tests (101.18611.4 ng/ml OTA,
p = 0.0236) (Fig. 2A). Chronic (21 days) OTA treatment
(0.5 mg/kg bw) resulted in 231.356 50.23 ng/ml OTA level in
the blood (p = 0.0001), however that elevation of OTA levels were
not seen in animals treated with the same dose of biodegraded
OTA (Fig. 2B). The batches of high quality animal feed were also
tested by SFH laboratory (Soft Flow Hungary Ltd., Hungary), and
traces of OTA were detected (3.0560.12 mg/kg feed).
3.4 Effect of OTA on the spleen and kidney weight
Spleen and kidney are sensitive indicators of OTA toxicity. The
acute OTA administration did not influence significantly the
kidney wet weight, but the spleen wet weights normalized to body
weight decreased significantly in both MMS and OTA treated
groups (p = 0.0096, p = 0.0109 and p = 0,0393) (Fig. S1B in
Supplementary Materials). On the other hand chronic OTA
administration decreased significantly the kidney wet weight
normalized to body weight only in the OTA treated group
(p = 0.0059) (Fig. S1C in Supplementary Materials). The spleen
wet weight normalized to body weight did not show statistically
significant differences between the MMS and OTA treated groups
(Fig. S1D in Supplementary Materials). The bacterial residuals did
not showed toxic effects on the spleen and the kidney in both
experiments as showed by their wet weight normalized to body
weight.
3.5 Histopathological analysis of renal cortex tissue
Animals treated with OTA (1 mg/kg bw or 10 mg/kg bw) for
72 h showed clear degenerative lesions mainly located in the inner
part of the cortex. Sporadic cell necrosis of the tubular epithelium
with cell detachment to the tubular lumen was detectable.
Multifocal tubular necrosis also occurred. Dispersed apoptotic
bodies, cell size reduction and condensed chromatin in nucleus
were observed at high OTA dosed groups and in the chronically
treated animals. Beyond degenerative changes tubular cell
regeneration has been detected in the chronic OTA treated
group. Mice treated with biodegraded OTA and their residuals
did not exhibit remarkable histopathological changes. The
Cupriavidus basilensis O˝r16 alone showed similar histology to
vehicle group (Fig. 3).
Figure 1. Ochratoxin-A biodegradation by Cupriavidus basilensis O˝R16 during 5 day incubation. Continuous decrease of the OTA
concentration is detected in the supernatant and pellet, while OTa concentration is increasing. Abbreviations: HPLC (supernatant OTA) – OTA
concentration in the supernatant originated from the degradation experiment measured by HPLC, HPLC (supernatant OTa) – OTa concentration in
the supernatant originated from the degradation experiment measured by HPLC, ELISA (supernatant) OTA – OTA concentration in the supernatant
originated from the degradation experiment measured by ELISA, ELISA (pellet) OTA – OTA concentration in the pellet originated from the
degradation experiment measured by ELISA. Measurements were carried out in triplicate, SD.3%.
doi:10.1371/journal.pone.0109817.g001
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3.6 Effect of acute OTA and OTA biodegradation
residuals on the expression of various marker genes in
the kidney
The high dose OTA and the MMS treatment significantly
increased gadd 45 (p = 0.00014) and gadd 153 (p = 0.0112)
mRNA levels (Fig. 4 A and B). The Cupriavidus basilensis O˝R16-
metabolized OTA residuals did not influence mRNA levels of
marker genes. LB with the bacterial strain did not change the
expressions of genotoxic marker genes. The acute OTA admin-
Figure 2. OTA concentration in the plasma (ng/ml) analyzed by
ELISA after 72 hours of treatment (A). OTA 1 and OTA 10 groups
show elevated OTA concentrations in blood plasma. The OTA 10 deg
group shows increased OTA content. Abbreviations: MMS- Group
treated with methyl methanesulfonate, OTA 1 and OTA 10- Groups
treated with 1 and 10 mg/kg body weight Ochratoxin A, OTA 1 deg and
OTA 10 deg- Groups treated with 1 and 10 mg/kg body weight
Ochratoxin A + Cupriavidus basilensis O˝R16 in modified Luria- Bertani
medium, LB bact- Cupriavidus basilensis O˝R16 in modified Luria- Bertani
medium (Kruskal-Wallis test was used). OTA concentrations in the
plasma (ng/ml) analyzed by ELISA after 21 days of treatment (B). The
OTA 0.5 group shows elevated OTA blood concentrations. Abbrevia-
tions: MMS – Group treated with methyl methanesulfonate, OTA 0.5 –
Group treated with 0.5 mg/kg body weight Ochratoxin A, OTA 0.5 deg
– Group treated with 0.5 mg/kg body weight Ochratoxin A +
Cupriavidus basilensis O˝R16 in modified Luria- Bertani medium, LB bact
– Cupriavidus basilensis O˝R16 in modified Luria- Bertani medium. (One
way ANOVA followed by the Tukey’s post hoc test were used) Data are
presented as mean 6 SD (n = 7–10, **p,0.01)
doi:10.1371/journal.pone.0109817.g002
Figure 3. Histology of the kidneys following OTA and
degraded OTA administrations. Photomicrographs showing hema-
toxylin-eosine stained kidney sections. Abbreviations: MMS- –methyl
methanesulfonate treated animals, OTA 1 and OTA 10 – Groups treated
with 1 and 10 mg/kg body weight Ochratoxin A, OTA 1 deg and OTA 10
deg – Groups treated with 1 and 10 mg/kg body weight Ochratoxin A +
Cupriavidus basilensis O˝R16 in modified Luria-Bertani medium, OTA 0.5 –
Group treated with 0.5 mg/kg body weight Ochratoxin A, OTA 0.5 deg
– Group treated with 0.5 mg/kg body weight Ochratoxin A +
Cupriavidus basilensis O˝R16 in modified Luria-Bertani medium, LB bact
– Cupriavidus basilensis O˝R16 in modified Luria- Bertani medium.
Symbols: asterisk- dilated tubules with detached necrotic epithelial
cells, white arrow- detached necrotic epithelial cells, black arrow-
necrotic tubular cells, white arrowhead- tubular cell regeneration. Scale
bar: 100 mm.
doi:10.1371/journal.pone.0109817.g003
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istration with high dosage significantly elevated the annexin2
mRNA expression (p = 0.0101). The end products of the OTA
biodegradation did not change the annexin2 mRNA expression in
the kidney cortex samples (Fig. 5A). Elevated expression level of
clusterin was observed in the high dose OTA treated group
(p = 0.000141), however metabolites of the biodegraded OTA did
not influence the clusterin mRNA levels (Fig. 5B). Animals treated
with high OTA dosage showed significant decrease in the sult1c2
mRNA levels (p = 0.000129). The biodegraded OTA did not
influence the sult1c2 mRNA expression in the renal cortex
(Fig. 6).
3.7 Effect of chronic OTA and OTA biodegradation
residuals on the expression of marker genes in the
kidney
The chronic low dose OTA exposure significantly induced
gadd45 (p = 0.0001) and gadd153 (p = 0.0141) mRNA levels in
the kidney. MMS and OTA degradation products did not affect
the mRNA levels of the genotoxic markers (Fig. 7A and 7B). The
annexin2 expression was increased in OTA treated animals (p =
0.000177) (Fig. 8A). On the other hand clusterin mRNA
Figure 4. Effect of acute (72 hours) OTA treatment on gadd45
mRNA expression (A). MMS and OTA 10 elevated the gadd45 mRNA
level. The metabolised OTA by Cupriavidus basilensis O˝R16 (OTA 1 deg
and OTA 10 deg groups) not influenced the mRNA level (One way
ANOVA followed by the Tukey’s post hoc test were used). Effect of acute
(72 hours) OTA treatment on gadd153 mRNA expression (B). OTA 10
elevated the gadd153 mRNA level. The metabolised OTA by Cupriavidus
basilensis O˝R16 (OTA 1 deg and OTA 10 deg groups) not influenced the
mRNA level. (Kruskal-Wallis test was used) Abbreviations: MMS – Group
treated with methyl methanesulfonate, OTA 1 and OTA 10 – Groups
treated with 1 and 10 mg/kg body weight Ochratoxin A, OTA 1 deg and
OTA 10 deg – Groups treated with 1 and 10 mg/kg body weight
Ochratoxin A + Cupriavidus basilensis O˝R16 in modified Luria-Bertani
medium, LB bact- Cupriavidus basilensis O˝R16 in modified Luria-Bertani
medium. Data are presented as mean 6 SD (n = 7–10, * p,0.05, ***p,
0.001)
doi:10.1371/journal.pone.0109817.g004
Figure 5. Effect of acute (72 hours) OTA treatment on annexin2
mRNA expression (A). OTA 10 elevated the annexin2 mRNA level. The
metabolised OTA by Cupriavidus basilensis O˝R16 (OTA 1 deg and OTA
10 deg groups) did not influence the mRNA level (Kruskal-Wallis test
was used). Effect of acute (72 hours) OTA treatment on clusterin mRNA
expression (B). OTA 10 elevated the clusterin mRNA level. The
metabolised OTA by Cupriavidus basilensis O˝R16 (OTA 1 deg and OTA
10 deg groups) did not influence the mRNA level. (One way ANOVA
followed by the Tukey’s post hoc test were used) Abbreviations: MMS –
Group treated with methyl methanesulfonate, OTA 1 and OTA 10 –
Groups treated with 1 and 10 mg/kg body weight Ochratoxin A, OTA 1
deg and OTA 10 deg- Groups treated with 1 and 10 mg/kg body weight
Ochratoxin A + Cupriavidus basilensis O˝R16 in modified Luria-Bertani
medium, LB bact – Cupriavidus basilensis O˝R16 in modified Luria-Bertani
medium. Data are presented as mean 6 SD (n = 7–10, ** p,0.01, ***
p,0.001).
doi:10.1371/journal.pone.0109817.g005
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expression was up-regulated in the MMS (non significant) and
OTA 0.5 (p = 0.0002) groups. The degraded OTA remnants did
not affect clusterin expression (Fig. 8B). In contrast, the sult1c2
mRNA expression was decreased significantly (p = 0.0005) in the
renal cortex during the OTA administration in the chronic
experiment; while the biodegraded OTA did not show effect on
the annexin2 and sult1c2 mRNA expressions in the kidney
(Fig. 8A and Fig. 9).
Discussion
Several studies on OTA degrading, adsorbing and detoxifying
agents have been published recently. Certain Lactobacillus species
have moderate OTA degradation capacity however, the toxicity of
the metabolites remains unclear [25]. Moreover, Bacillus
licheniformis degraded 92.5% of OTA at 37uC and OTa, as
degradation product, was detected [26]; while Brevibacterium spp.
strains showed 100% degradation of OTA [27]. Furthermore an
OTA degrading enzyme was identified in Aspergillus niger, which
is capable to metabolize the OTA to phenylalanine and OTa [28].
Some Trichosporon species have the ability to cleave OTA
selectively into phenylalanine and OTa but then the presumed
nephrotoxic effect of other alternative metabolites were not
investigated at gene expression level [29]. Trichosporon mycotox-
inivorans was classified as a novel species due to ability to detoxify
OTA [30]. This yeast, when introduced to the diet of broiler
chickens completely abolished OTA effects on the immune system
[31]. However, a recent study was raising doubts over the safety of
T. mycotoxinivorans as it was associated with cystic fibrosis and the
death of a patient with histological documented Trichosporon
pneumonia [32].
In our experiment the OTA-degrading potential of C. basilensis
O˝R16 and acute/chronic toxicity of the degraded products were
analysed. The OTA was degraded efficiently by the 5th day of
biodegradation. Moreover, metabolised form of OTA was also
measured. Two pathways may be involved in OTA microbiolog-
ical degradation. First, OTA can be biodegraded through the
hydrolysis of the amide bond that links the L-b-phenylalanine
molecule to the OTa moiety. Since OTa and L-b-phenylalanine
are virtually non-toxic, this mechanism can be considered to be a
detoxification pathway. Second, a more hypothetical process
involves OTA being degraded via the hydrolysis of the lactone ring
[33]. In this case, the final degradation product is an opened
lactones form of OTA, which has similar toxicity than OTA when
administered to rats [34,35]. In the present study OTa was
detected by HPLC, and also the time-curve detected increasing
OT-a concentration parallel with the OTA-decrease. Based on
this phenomenon cleavage of the amide bond that links the L-b-
phenylalanine molecule to the OTa moiety is hypothesized
Figure 6. Effect of acute (72 hours) OTA treatment on sult1c2
mRNA expression. OTA 10 elevated the sult1c2 mRNA level alone.
The metabolised OTA by Cupriavidus basilensis O˝R16 (OTA 1 deg and
OTA 10 deg groups) not influenced the mRNA level. (One way ANOVA
followed by the Tukey’s post hoc test were used) Abbreviations: MMS-
Group treated with methyl methanesulfonate, OTA 1 and OTA 10-
Groups treated with 1 and 10 mg/kg body weight Ochratoxin A, OTA 1
deg and OTA 10 deg- Groups treated with 1 and 10 mg/kg body weight
Ochratoxin A + Cupriavidus basilensis O˝R16 in modified Luria- Bertani
medium, LB bact- Cupriavidus basilensis O˝R16 in modified Luria- Bertani
medium. Data are presented as mean 6 SD (n = 7–10, **** p,0.0001)
doi:10.1371/journal.pone.0109817.g006
Figure 7. Effect of chronic (21 days) OTA treatment on gadd45
mRNA expression (A). The OTA 0.5 mg/kg bw chronic administration
elevated the gadd45 mRNA level. The metabolised OTA by Cupriavidus
basilensis O˝R16 (OTA 0.5 deg group) not influenced the mRNA levels
(One way ANOVA followed by the Tukey’s post hoc test were used).
Effect of chronic (21 days) OTA treatment on gadd153 mRNA expression
(B). The OTA 0.5 mg/kg bw chronic administration elevated the
gadd153 mRNA level. The metabolised OTA by Cupriavidus basilensis
O˝R16 (OTA 0.5 deg group) did not influence the mRNA level (Kruskal-
Wallis test was used). Abbreviations: MMS – Group treated with methyl
methanesulfonate, OTA 0.5 – Group treated with 0.5 mg/kg body
weight Ochratoxin A, OTA 0.5 deg – Group treated with 0.5 mg/kg
body weight Ochratoxin A + Cupriavidus basilensis O˝R16 in modified
Luria-Bertani medium, LB bact – Cupriavidus basilensis O˝R16 in modified
Luria-Bertani medium. Data are presented as mean 6 SD (n = 7–9, *p,
0.05***p,0.001)
doi:10.1371/journal.pone.0109817.g007
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(Fig. 10). This observation was confirmed by in vivo toxicological
tests.
The major metabolite of the bacterial OTA degradation is the
OTa, which is a non-toxic metabolite of the OTA but then
formations of other toxic residuals are possible [36,37]. Chemical
analysis and immunochemical methods are less sensitive to detect
all potential harmful degradation products, therefore it is
important to monitor for toxicity by in vivo methods.
After oral administration of various doses of OTA in acute and
chronic experiments, significant elevation of the OTA concentra-
tions were found in plasma. Even in control animals OTA levels
above the detection limit were found, which could be attributed to
natural contamination, as it was reported previously [38–40].
OTA concentration in the plasma showed positive correlation with
the administered mycotoxin doses. On the other hand elevated
OTA concentration was detected in the blood samples after acute
exposure with high doses of biodegraded OTA metabolites;
however, this OTA concentration was only 5.1 % compared to the
OTA level detected in the OTA 10 group (Fig. 2A). Presumably
the residual non degraded OTA was accumulated in the blood.
This result was confirmed by ELISA tests which detected 94%
biodegradation efficiency of the Cupriavidus basilensis O˝R16
(Fig. 1).
The long-term OTA exposure during the chronic mycotoxin
treatment significantly decreased the kidney weight but then the
acute treatment with the detoxified metabolites of OTA did not
affect it, which alteration is the most toxins sensitive. These
observations were established by previous reports in which chronic
OTA exposure induced nephropathy in animals and humans, as
well [8,12,13]. The OTA degradation by Cupriavidus basilensis
O˝R16 completely abolished these effects. This phenomenon was
confirmed by histopathology analysis. The high dose of acute and
the lower dose of chronic OTA treatment induced toxicities
related malformations in renal cortex tissue (Fig. 3). These results
were also detected in previous studies of Lu¨he and co-workers in
acute experiments and also in chronic experiments on rodent
models by Rached and colleagues [19,41]. In the present work,
neither the Cupriavidus basilensis O˝R16 with modified LB, nor
the degraded OTA residuals formed pathological disorders.
The spleen, the other mycotoxin sensitive organ, was examined
with different OTA dosages in acute and chronic experiments.
The spleen weight was significantly decreased after acute OTA
and MMS exposure, but the chronic OTA and MMS treatments
did not decrease the spleen weight significantly. The rapid OTA
accumulation in the blood after high dosage treatment could
explain the suppression of immune system and the lymphoid organ
weight loss. Similar observations were published in case of broiler
chickens after chronic OTA administration [42,43]. Moreover, by
analysing blood samples and lymphoid organs of humans and
Figure 8. Effect of chronic (21 days) OTA treatment on annexin2
mRNA expression (A). The OTA 0.5 mg/kg bw chronic administration
elevated the annexin2 mRNA level. The metabolised OTA by Cupriavidus
basilensis O˝R16 (OTA 0.5 deg group) did not influence the mRNA level.
(One way ANOVA followed by the Tukey’s post hoc test were used)
Effect of chronic (21 days) OTA treatment on clusterin mRNA expression
(B). The MMS and OTA 0.5 mg/kg bw chronic administration elevated
the clusterin mRNA level. The metabolised OTA by Cupriavidus basilensis
O˝R16 (OTA 0.5 deg group) did not influence the mRNA level. (One way
ANOVA followed by the Tukey’s post hoc test were used) Abbreviations:
MMS – Group treated with methyl methanesulfonate, OTA 0.5 – Group
treated with 0.5 mg/kg body weight Ochratoxin A, OTA 0.5 deg –
Group treated with 0.5 mg/kg body weight Ochratoxin A + Cupriavidus
basilensis O˝R16 in modified Luria-Bertani medium, LB bact – Cupriavidus
basilensis O˝R16 in modified Luria- Bertani medium. Data are presented
as mean 6 SD (n = 7–9, *** p,0.001)
doi:10.1371/journal.pone.0109817.g008
Figure 9. Effect of chronic (21 days) OTA treatment on sult1c2
mRNA expression. The OTA 0.5 mg/kg bw chronic administration
elevated the sult1c2 mRNA level. The metabolised OTA by Cupriavidus
basilensis O˝R16 (OTA 0.5 deg group) did not influence the mRNA level.
(One way ANOVA followed by the Tukey’s post hoc test were used)
Abbreviations: MMS – Group treated with methyl methanesulfonate,
OTA 0.5 – Group treated with 0.5 mg/kg body weight Ochratoxin A,
OTA 0.5 deg- Group treated with 0.5 mg/kg body weight Ochratoxin A
+ Cupriavidus basilensis O˝R16 in modified Luria-Bertani medium, LB
bact- Cupriavidus basilensis O˝R16 in modified Luria-Bertani medium.
Data are presented as mean 6 SD (n = 6–9, **p,0.01)
doi:10.1371/journal.pone.0109817.g009
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other mammalians, altered immune functions were also detected
[44]. Histopathological examinations were demonstrated that the
immunotoxic effect and histological malformation regarding the
degraded OTA residuals and the Cupriavidus basilensis O˝R16
strain was not detected at histopathological level. Our bacterial
OTA degradation strategy is an effective detoxification process by
toxicological and physiological point of view.
Previous molecular genetic analysis demonstrated that the OTA
influences the expression of genotoxic, apoptotic, detoxification
and inflammation related genes in a dose dependent manner. This
study revealed 254 genes which expression changed by at least
two-fold after acute (3 day) OTA exposure (1 and 10 mg/kg bw).
Eighty-nine genes were up regulated and 165 were down
regulated. In the present work dose and time dependent
Discriminator Genes were selected [19]. These genes are useful
markers in the renal cortex for monitoring possible toxic effects of
the end products after biodegradation. The selected, robust up- or
down-regulated marker genes along with the adjusted experimen-
tal circumstances encompass the complete toxic action of OTA
and the applied indicators are sensitive for many of the possible
toxicities of the bio-converted OTA residuals. The expressions of
OTA induced marker genes were detected by quantitative-real-
time-PCR measurement; since one of the major effects of OTA is
the DNA damaging action [45]. The gadd 45 and gadd 153 genes
serves as markers to demonstrate the genotoxic effect and DNA
damage induction of OTA, besides these genes are monitoring the
biodegradation of OTA. By the degradation of OTA, the toxicity
is eliminating which results unaltered gadd 45 and gadd 153
mRNA levels. MMS treated animals served as positive control,
because MMS is a well-studied genotoxic chemical that induces
alterations in gadd 45 and gadd 153 mRNA expressions [46].
While OTA up-regulated the expression of gadd 45 and gadd 153
in a dose dependent manner, the metabolised OTA by
Cupriavidus basilensis O˝R16 completely eliminated this up-
regulation in both experiments. Furthermore, the OTA is involved
in renal tumour formation. The clusterin and annexin2 play
important role in the apoptotic processes and in the renal tumour
formation [47]. Previous studies have demonstrated annexin 2
(anxa2) up-regulation by acute OTA treatment in the renal cortex
of rats, which resulted similar mRNA expression level that was
described in our acute experiment in mice [19]. Annexin2 is a
cofactor for DNA polymerase alpha subunit that plays an
important role in the DNA repair and in the development of
different cancers [48]. Furthermore annexin2 is a substrate for an
oncogene associated kinase [49]. Elevated level of annexin2 was
described in the kidney carcinoma formation in rat [50]. The
OTA biodegradation by Cupriavidus basilensis O˝R16 strain
abolished the up-regulation of both marker genes in both acute
and chronic treatments, indicating that the biodegradation was a
detoxification as well.
Sulfotransferase 1c2 serves as a marker for the cellular and
detoxification processes, which has been identified as an OTA-
induced gene in acute (72 hours) mycotoxin treatment [19].
Sulfotransferase takes part in xenobiotic detoxification, carcinogen
activation, prodrug processing, and cellular signalling pathways
[51]. Our work demonstrated that sulfotransferase 1c2 expression
decreased after acute and chronic OTA exposure. OTA biodeg-
radation by Cupriavidus basilensis O˝R16 strain abolished the
sulfotransferase mRNA down-regulation in both experiments.
Based on our present results, the major metabolite of OTA
biodegradation by Cupriavidus basilensis O˝R16 is Ochratoxin a.
This metabolite is not toxic in vitro and here we found that
biodegradation product does not display nephrotoxic effects in
vivo. In summary, by application of Cupriavidus basilensis O˝R16,
OTA is degraded efficiently without bioactive intermediates and
by-products; therefore Cupriavidus basilensis O˝R16 is worth
further study for possible use for the decontamination of raw
materials, to reduce OTA concentration.
Supporting Information
Figure S1 The acute OTA administration did not influence
significantly the kidney normalized weight (A). (Kruskal-Wallis test
was used). The acute OTA administration significantly decreased
the spleen normalized weights of animals in the MMS, OTA 1 and
OTA 10 groups (B). (Kruskal-Wallis test was used). Abbreviations:
MMS – Group treated with methyl methanesulfonate, OTA 1 and
OTA 10 – Groups treated with 1 and 10 mg/body weight kg
Ochratoxin A, OTA 1 deg and OTA 10 deg- Groups treated with
1 and 10 mg/body weight kg Ochratoxin A + Cupriavidus
basilensis O˝R16 in modified Luria-Bertani medium, LB bact -
Cupriavidus basilensis O˝R16 in modified Luria-Bertani medium.
Data are presented as mean 6 SD (n = 7-10, *p,0.05,**p,0.01,).
The chronic OTA administration significantly decreased the
kidney normalized weight of animals in the OTA 0.5 groups (C).
(One way ANOVA followed by the Tukey’s post hoc test were
used). The chronic OTA administration decreased the spleen
normalized weight of animals in the MMS and OTA 0.5 groups
(D). The alterations were not significant. (Kruskal-Wallis test was
used). Abbreviations: MMS – Group treated with methyl
methanesulfonate, OTA 0.5 – Group treated with 0.5 mg/body
weight kg Ochratoxin A, OTA 0.5 deg – Group treated with
0.5 mg/body weight kg Ochratoxin A + Cupriavidus basilensis
O˝R16 in modified Luria-Bertani medium, LB bact – Cupriavidus
basilensis O˝R16 in modified Luria- Bertani medium. Data are
presented as mean 6 SD (n = 7-10, **p,0.01).
(TIF)
Figure 10. Proposed cleavage of Ochratoxin A by Cupriavidus basilensis O˝R16. The amide bond hydrolysis (up arrow) resulting Ochratoxin a
as a major degradation product.
doi:10.1371/journal.pone.0109817.g010
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Table S1 Detailed information about analytical meth-
ods for ochratoxin-A, and its derivative ochratoxin-a.
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